ASCO 2022 | Current treatment strategies KRASG12C–mutated NSCLC

The KRAS p.G12C mutation is the most frequently observed mutation in metastatic non-small cell lung cancer (NSCLC) and has resulted in the creation of multiple targeted therapies. Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, provides an overview of current KRASG12C inhibitors, including adagrasib and sotorasib. Adagrasib has demonstrated promising results in previously treated patients as well as in untreated patients with brain metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.